Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
03/2012
03/29/2012US20120077798 Azetidine and cyclobutane derivatives as jak inhibitors
03/29/2012US20120077792 Lanthanide metal complexes useful in treating cancer
03/29/2012US20120077785 Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis
03/29/2012US20120077782 Method of activation of oxazaphosphorines
03/29/2012US20120077779 Inhibitors of Fibroblast Activation Protein Alpha
03/29/2012US20120077777 Ngcycloartanone derivatives with anticancer activity
03/29/2012US20120077775 Macrocyclic compounds useful as inhibitors of kinases and hsp90
03/29/2012US20120077768 Stabilized and lyophilized formulation of anthracycline compounds
03/29/2012US20120077759 3-3-Di-Substituted-Oxindoles as Inhibitors of Translation Initiation
03/29/2012US20120077757 Methods for Affecting Homology-Directed DNA Double Stranded Break Repair
03/29/2012US20120077755 Compounds For, and Methods of, Treating Cancer and Inhibiting Invasion and Metastases
03/29/2012US20120077750 Use of a growth-stimulating protein
03/29/2012US20120077741 Treatment of Central Nervous System Disorders
03/29/2012US20120077740 Methods for making Apo-2 Ligand using divalent metal ions
03/29/2012US20120077734 Methods and assays for treating conditions in which macrophages play a pathogenic role
03/29/2012US20120077732 Cyclic peptides and uses thereof
03/29/2012US20120077731 Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
03/29/2012US20120077676 Antifungal 1,2,4-Triazolyl Derivatives Having a 5-Sulfur Substituent
03/29/2012US20120076873 Health Food
03/29/2012US20120076862 Methods of enhancing drug delivery and effectiveness of therapeutic agents
03/29/2012US20120076852 Drug carrier and drug carrier kit for inhibiting fibrosis
03/29/2012US20120076851 CHROMOSOME 3p21.3 GENES ARE TUMOR SUPPRESSORS
03/29/2012US20120076848 Method and system for effecting changes in pigmented tissue
03/29/2012US20120076832 Synthesis and use of therapeutic metal ion containing polymeric particles
03/29/2012US20120076828 Kanamycin antisense nucleic acid for the treatment of cancer
03/29/2012US20120076827 Compositions and methods for generating an immune response in a subject
03/29/2012US20120076823 Vector
03/29/2012US20120076807 Plasmids with immunological action
03/29/2012US20120076804 Cancer targeted innate immunity
03/29/2012US20120076797 Modulation of kit signaling and hematopoietic cell development by IL-4 receptor modulation
03/29/2012US20120076796 Amino acid sequences directed against the angiopoietin/tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
03/29/2012US20120076795 Anti-PECAM Therapy, Compositions, Methods, and Uses
03/29/2012US20120076792 Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
03/29/2012US20120076789 Nucleic acid and corresponding protein entitled 121p1f1 useful in treatment and detection of cancer
03/29/2012US20120076788 C-cbl and antagonists thereof for the treatment and diagnosis of cancer
03/29/2012US20120076784 Highly concentrated, liquid formulations of anti-egfr antibodies
03/29/2012US20120076782 Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
03/29/2012US20120076781 Methods of treating cancers with her3 antisense oligonucleotides
03/29/2012US20120076780 Recombinant fusion protein and polynucleotide construct for immunotoxin production
03/29/2012US20120076778 Antibodies Against Insulin-Like Growth Factor I Receptor and Uses Thereof
03/29/2012US20120076777 Anti-fibroblastic fluorochemical emulsion therapies
03/29/2012US20120076775 Combination of HGF Inhibitor and EGF Inhibitor to Treat Cancer
03/29/2012US20120076773 Novel Drug Delivery Devices
03/29/2012US20120076770 Modulation of autophagy and and serotonin for treatment of multiple myeloma related diseases
03/29/2012US20120076769 Herbal composition for cancer treatment
03/29/2012US20120076752 Mesothelin Vaccines and Model Systems
03/29/2012US20120076742 Topical drug delivery system with dual carriers
03/29/2012US20120076738 Combination treatment for dermatological conditions
03/29/2012US20120076730 Peptides for transport of therapeutics and their carriers in mouse models and humans
03/29/2012US20120076729 Methods of treating cancers
03/29/2012US20120076728 Human protein scaffold with controlled serum pharmacokinetics
03/29/2012US20120076725 Lung cancer markers, and uses thereof
03/29/2012US20120076723 Devices and methods for the treatment of cancer
03/29/2012DE102010046866A1 Diagnosing diseases of central nervous system e.g. primary lymphoma, comprises determining content of microRNA highly diagnostic for presence or absence of disease in a sample of cerebrospinal fluid, and comparing with a reference value
03/29/2012DE102010046837A1 Phenylchinazolinderivate Phenylchinazolinderivate
03/29/2012DE102010046720A1 Verfahren zur Herstellung von pan-CDK-Inhibitoren der Formel (l), sowie Intermediate der Herstellung A process for producing pan-CDK inhibitors of the formula (l), as well as intermediates of the preparation of
03/29/2012CA2812362A1 Matrix metalloproteinase inhibitors
03/29/2012CA2812361A1 Matrix metalloproteinase inhibitors
03/29/2012CA2812096A1 Oncolytic adenoviral vectors and methods and uses related thereto
03/29/2012CA2811734A1 Multimeric il-15 soluble fusion molecules and methods of making and using same
03/29/2012CA2811567A1 Deubiquitinase inhibitors and methods for use of the same
03/29/2012CA2811556A1 Breast cancer therapeutics
03/29/2012CA2810706A1 Substituted amide compound
03/29/2012CA2809762A1 Methods and compositions for treating lung cancer
03/29/2012CA2809557A1 Pyrazolopyridines as inhibitors of the kinase lrrk2
03/28/2012EP2434282A2 Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers
03/28/2012EP2433967A2 Humanised antibodies with anti-tumour activity
03/28/2012EP2433964A1 Peptide inducing xage-1b-specific immune reaction and utilization of same
03/28/2012EP2433653A1 Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
03/28/2012EP2433636A1 Treatment of Malignant Diseases
03/28/2012EP2433630A1 Self-emulsifying composition of 3 fatty acid
03/28/2012EP2433628A1 Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer
03/28/2012EP2433627A1 Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer
03/28/2012EP2433619A1 Novel antitumoral agent and its therapeutic uses
03/28/2012EP2433133A2 Mitochondrial activity inhibitors of cancer-initiating cells and use thereof
03/28/2012EP2432799A1 Cycloartanone derivatives with anticancer activity
03/28/2012EP2432784A1 Fused bicyclic pyrazole derivatives as kinase inhibitors
03/28/2012EP2432779A1 Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases
03/28/2012EP2432768A1 Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
03/28/2012EP2432766A1 Anticancer compound and pharmaceutical composition containing the same
03/28/2012EP2432765A1 Isoquinolin-1 (2h) -one derivatives as parp-1 inhibitors
03/28/2012EP2432764A1 Substituted quinolines for use as vegf inhibitors
03/28/2012EP2432556A1 Protease inhibitors
03/28/2012EP2432555A1 N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
03/28/2012EP2432553A2 Liquid dosage forms of isotretinoin
03/28/2012EP2432505A1 Combinations of immunostimulatory agents, oncolytic virus, and additional anticancer therapy
03/28/2012EP2432472A1 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
03/28/2012EP2432466A1 Schweinfurthins and uses thereof
03/28/2012EP2432464A2 Nitrile derivatives and their pharmaceutical use and compositions
03/28/2012EP2432451A2 Compositions for the treatment of metastatic cancer and methods of use thereof
03/28/2012EP2326649B1 NOVEL PYRROLO[2,3-a]CARBAZOLES AND USE THEREOF AS PIM KINASE INHIBITORS
03/28/2012EP2297148B8 Novel derivatives of (bridged piperazinyl)-1-alcanone and use thereof as p75 inhibitors
03/28/2012EP2252612B1 Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors
03/28/2012EP2188276B1 Substituted hydantoins
03/28/2012EP2186529B1 Synergic pharmaceutical composition, useful for inhibiting corneal and retinal neovascularization (angiogenesis), and in other organs, in a human being or animal
03/28/2012EP2118087B1 Pi 3-kinase inhibitors and methods of their use
03/28/2012EP2099461B1 Lna nucleoside phosphoramidates
03/28/2012EP1799685B1 Polymorphic forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
03/28/2012EP1527047B1 3-z- 1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-me thyl-amino)-anilino)-1-phenyl-methylene -6-methoxycarbonyl-2 -indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition
03/28/2012EP1517700B1 Mucin fusion polypeptide vaccines, compositions and methods of use thereof
1 ... 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 ... 2211